<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2025-3253</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-3253</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group></article-categories><title-group><article-title>From SCORE2 to SCORE2-RF: development of a Russian model for cardiovascular risk stratification</article-title><trans-title-group xml:lang="ru"><trans-title>От SCORE2 к SCORE2-РФ: разработка российской модели стратификации сердечно-сосудистого риска</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Драпкина Оксана Михайловна</p><p>Москва</p></bio><bio xml:lang="en"><p>Oksana M. Drapkina</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8011-2798</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баланова</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Balanova</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Баланова Юлия Андреевна</p><p>Москва</p></bio><bio xml:lang="en"><p>Yulia A. Balanova</p><p>Moscow</p></bio><email xlink:type="simple">JBalanova@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2087-6483</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шальнова</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shalnova</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шальнова Светлана Анатольевна</p><p>Москва</p></bio><bio xml:lang="en"><p>Svetlana A. Shalnova</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9844-3122</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куценко</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutsenko</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Куценко Владимир Александрович</p><p>Москва</p></bio><bio xml:lang="en"><p>Vladimir A. Kutsenko</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9148-4703</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Свинин</surname><given-names>Г. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Svinin</surname><given-names>G. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Свинин Глеб Евгеньевич</p><p>Москва</p></bio><bio xml:lang="en"><p>Gleb E. Svinin</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9332-0622</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Имаева</surname><given-names>А. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Imaeva</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Имаева Асия Эмвяровна</p><p>Москва</p></bio><bio xml:lang="en"><p>Asiia E. Imaeva</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9624-9374</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Капустина</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kapustina</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Капустина Анна Владимировна</p><p>Москва</p></bio><bio xml:lang="en"><p>Anna V. Kapustina</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7486-4667</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Евстифеева</surname><given-names>С. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Evstifeeva</surname><given-names>S. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Евстифеева Светлана Евгеньевна</p><p>Москва</p></bio><bio xml:lang="en"><p>Svetlana E. Evstifeeva</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0240-3941</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Муромцева</surname><given-names>Г. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Muromtseva</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Муромцева Галина Аркадьевна</p><p>Москва</p></bio><bio xml:lang="en"><p>Galina A. Muromtseva</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6713-7090</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гоманова</surname><given-names>Л. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Gomanova</surname><given-names>L. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гоманова Лилия Ильинична</p><p>Москва</p></bio><bio xml:lang="en"><p>Liliya I Gomanova</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0545-2586</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимов</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Максимов Сергей Алексеевич</p><p>Москва</p></bio><bio xml:lang="en"><p>Sergey A. Maximov</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2145-1284</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Назаров</surname><given-names>Б. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Nazarov</surname><given-names>B. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Назаров Бадриддин Мухиддинович</p><p>Москва</p></bio><bio xml:lang="en"><p>Badriddin M Nazarov</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ООО «Здоровая семья»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>«Healthy Family» LLC</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>22</day><month>01</month><year>2026</year></pub-date><volume>21</volume><issue>6</issue><fpage>502</fpage><lpage>512</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Drapkina O.M., Balanova Y.A., Shalnova S.A., Kutsenko V.A., Svinin G.E., Imaeva A.E., Kapustina A.V., Evstifeeva S.E., Muromtseva G.A., Gomanova L.I., Maksimov S.A., Nazarov B.M., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Драпкина О.М., Баланова Ю.А., Шальнова С.А., Куценко В.А., Свинин Г.Е., Имаева А.Э., Капустина А.В., Евстифеева С.Е., Муромцева Г.А., Гоманова Л.И., Максимов С.А., Назаров Б.М.</copyright-holder><copyright-holder xml:lang="en">Drapkina O.M., Balanova Y.A., Shalnova S.A., Kutsenko V.A., Svinin G.E., Imaeva A.E., Kapustina A.V., Evstifeeva S.E., Muromtseva G.A., Gomanova L.I., Maksimov S.A., Nazarov B.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/3253">https://www.rpcardio.online/jour/article/view/3253</self-uri><abstract><sec><title>Aim</title><p>Aim. To validate the European SCORE2 scale for assessing the 10-year risk of fatal and non-fatal cardiovascular events in the Russian population and to develop an adapted local version of the scale (SCORE2-RF) with defined thresholds for risk stratification.</p></sec><sec><title>Material and methods</title><p>Material and methods. The analysis was performed on data from the prospective follow-up of the Russian cohort of the ESSE-RF study (2012-2014, 10 regions). The final sample included participants aged 40-64 years without a history of cardiovascular disease (CVD) or diabetes mellitus. The median follow-up was 11.5 years. The combined endpoint included death from cardiovascular causes, non-fatal myocardial infarction, and/or stroke. Data collection involved questionnaires, anthropometry, and laboratory tests. Тo assess the associations of risk factors with the combined cardiovascular endpoint, a Fine–Gray competing risks model with stratification by region and type of settlement was used. The calculated hazard ratios were converted into absolute probabilities. The prediction accuracy of the original and adapted scales was assessed using Bland–Altman plots and calibration coefficients.</p></sec><sec><title>Results</title><p>Results. The Fine–Gray model confirmed a statistically significant association with the combined endpoint for most SCORE2 components (age, systolic blood pressure, total cholesterol, smoking) in men. In women, smoking did not show a significant association (HR 1.18; 95% CI: 0.73-1.91). Validation showed that the original SCORE2 scale satisfactorily predicted risk for Russian men, slightly overestimating it (by 0.96 percentage points or by a factor of 1.11), but the prognosis for women was significantly overestimated – on average by 3.12 percentage points or by a factor of 1.72. Based on the constructed Fine–Gray model, an adapted SCORE2-RF scale was developed. To avoid shifting most of the population into the high-risk category when using the original SCORE2 thresholds, new stratification criteria were proposed, based on the percentile distribution of risk within each age-sex group (low/moderate, high, very high risk).</p></sec><sec><title>Conclusion</title><p>Conclusion. The adapted SCORE2-RF scale, developed based on Russian population data and using new threshold values, is a more accurate and practical tool for risk stratification and clinical decision-making in the Russian healthcare setting.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Валидировать европейскую шкалу SCORE2 для оценки 10-летнего риска фатальных и нефатальных сердечно-сосудистых событий в российской популяции, а также создать адаптированную отечественную версию шкалы (SCORE2-РФ) с выделением пороговых значений для стратификации риска.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Анализ выполнен на данных проспективного наблюдения российской когорты исследования ЭССЕ-РФ (2012-2014 гг., 10 регионов). В окончательную выборку вошли участники в возрасте 40-64 лет без сердечно-сосудистых заболеваний и сахарного диабета в анамнезе. Медиана наблюдения составила 11,5 лет. Комбинированная конечная точка (ККТ) включала смерть от сердечно-сосудистых причин, нефатальный инфаркт миокарда и/или инсульт. Для сбора данных использовалось анкетирование, антропометрия и лабораторные исследования. Для оценки ассоциаций факторов риска с ККТ использовалась модель конкурирующих рисков Файна–Грея со стратификацией по региону и типу поселения. Вычисленные относительные риски были преобразованы в абсолютные вероятности. Точность прогноза исходной и адаптированной шкал оценивалась с помощью графиков Блэнда–Альтмана и расчета коэффициентов калибровки.</p></sec><sec><title>Результаты</title><p>Результаты. Модель Файна–Грея подтвердила статистически значимую ассоциацию с ККТ для большинства компонентов SCORE2 (возраст, систолическое артериальное давление, общий холестерин, курение) у мужчин. У женщин для курения не выявлено значимой связи (HR 1,18; 95% ДИ: 0,73-1,91). Валидация показала, что оригинальная шкала SCORE2 удовлетворительно предсказывает риск для российских мужчин, незначительно его завышая (на 0,96 п.п. или в 1,11 раза), но для женщин прогноз оказался существенно завышен – в среднем на 3,12 п.п. или в 1,72 раза. На основе построенной модели Файна–Грея сконструирована адаптированная шкала SCORE2-РФ. Чтобы избежать смещения большей части популяции в категорию высокого риска при использовании оригинальных порогов SCORE2, предложены новые критерии стратификации, основанные на процентильном распределении риска внутри каждой возрастно-половой группы (низкий/умеренный, высокий, очень высокий риск).</p></sec><sec><title>Заключение</title><p>Заключение. Адаптированная шкала SCORE2-РФ, разработанная на основе российских популяционных данных и использующая новые пороговые значения, является более точным и практичным инструментом для стратификации риска, а также принятия клинических решений в условиях российского здравоохранения.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>шкала SCORE2</kwd><kwd>SCORE2-РФ</kwd><kwd>валидация</kwd><kwd>когортное исследование</kwd><kwd>стратификация риска</kwd><kwd>российская популяция</kwd><kwd>сердечно-сосудистый риск</kwd><kwd>ЭССЕ-РФ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>SCORE2 scale</kwd><kwd>SCORE2-RF</kwd><kwd>validation</kwd><kwd>cohort study</kwd><kwd>risk stratification</kwd><kwd>Russian population</kwd><kwd>cardiovascular risk</kwd><kwd>ESSE-RF</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Авторы выражают глубокую признательность исследователям и медицинским работникам, участвовавшим в сборе данных в рамках проспективного наблюдения исследования ЭССЕ-РФ.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Graham IM, Cooney MT, Bradley D, et al.; European Society of Cardiology Cardiovascular Risk Collaboration. Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4/8. J Am Coll Cardiol. 2021;77(24):3046-57. DOI:10.1016/j.jacc.2021.04.052.</mixed-citation><mixed-citation xml:lang="en">Graham IM, Cooney MT, Bradley D, et al.; European Society of Cardiology Cardiovascular Risk Collaboration. Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4/8. J Am Coll Cardiol. 2021;77(24):3046-57. DOI:10.1016/j.jacc.2021.04.052.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Баланова Ю.А., Шальнова С.А., Деев А.Д. и др. Распространенность курения в России. Что изменилось за 20 лет? Профилактическая медицина. 2015;18(6):47-52. DOI: 10.17116/profmed201518647-52.</mixed-citation><mixed-citation xml:lang="en">Balanova IuA, Shalnova SA, Deev AD, et al. Smoking prevalence in Russia. What has changed over 20 years? Russian Journal of Preventive Medicine. 2015;18(6):47-52. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Баланова Ю.А., Драпкина О.М., Куценко В.А. и др. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространённости, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кардиоваскулярная терапия и профилактика. 2023;22(8S):3785. DOI:10.15829/1728-8800-2023-3785.</mixed-citation><mixed-citation xml:lang="en">Balanova YuA, Drapkina OM, Kutsenko VA, et al. Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. (in Russ).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Баланова Ю.А., Имаева А.Э., Концевая А.В. и др. Ожирение в российской популяции — распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2018;(6):123-30. DOI: 10.15829/1560-4071-2018-6-123-130.</mixed-citation><mixed-citation xml:lang="en">Balanova YuA, Shalnova SA, Deev AD, et al. Obesity in Russian population — prevalence and association with the non-communicable diseases risk factors. Russian Journal of Cardiology. 2018;(6):123-30. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Семенов В.Ю., Самородская И.В. Динамика мужской и женской смертности от болезней системы кровообращения в Российской Федерации (2013-2022гг.). Российский кардиологический журнал. 2025;30(5):30-5]. DOI: 10.15829/1560-4071-2025-6086.</mixed-citation><mixed-citation xml:lang="en">Semenov VYu, Samorodskaya IV. Changes of male and female cardiovascular mortality in the Russian Federation over 2013-2022. Russian Journal of Cardiology. 2025;30(5):30-5. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-54. DOI: 10.1093/eurheartj/ehab309.</mixed-citation><mixed-citation xml:lang="en">SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-54. DOI: 10.1093/eurheartj/ehab309.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Шальнова С.А. Комментарии к разделу "Оценка сердечно-сосудистого риска» в Европейских рекомендациях по профилактике сердечно-сосудистых заболеваний в клинической практике 2021 года. Кардиоваскулярная терапия и профилактика. 2022;21(1):3171. DOI: 10.15829/1728-8800-2022-3171.</mixed-citation><mixed-citation xml:lang="en">Shalnova SA. Comments on the section “Cardiovascular risk estimation” in the 2021 European Society of Cardiology guidelines on cardiovascular disease prevention in clinical practice. Cardiovascular Therapy and Prevention. 2022;21(1):3171. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chipayo-Gonzales D, Ramakrishna H, Nuñez-Gil IJ. Score2: A New Updated Algorithm to Predict Cardiovascular Disease Risk in Europe. J Cardiothorac Vasc Anesth. 2022;36(1):18-21. DOI: 10.1053/j.jvca.2021.09.033.</mixed-citation><mixed-citation xml:lang="en">Chipayo-Gonzales D, Ramakrishna H, Nuñez-Gil IJ. Score2: A New Updated Algorithm to Predict Cardiovascular Disease Risk in Europe. J Cardiothorac Vasc Anesth. 2022;36(1):18-21. DOI: 10.1053/j.jvca.2021.09.033.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Шальнова С. А., Баланова Ю. А. и др. Атлас факторов риска хронических неинфекционных заболеваний по данным исследований ЭССЕ-РФ, ЭССЕ-РФ2, ЭССЕ-РФ3: учебное наглядное пособие. М.: РОПНИЗ, ООО «Силицея-Полиграф». 2025. ISBN: 978-5-6053845-4-0. DOI:10.15829/ROPNIZ-d102-2025.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Shalnova SA, Balanova YuA, et al. Atlas of Risk Factors for Chronic Non-Infectious Diseases Based on the ESSE-RF, ESSE-2, and ESSE-RF 3 Studies: Educational Manual. Moscow: ROPNIZ, ООО «Silicea-Poligraf». 2025. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785-802. DOI: 10.1038/s41569-021-00559-8.</mixed-citation><mixed-citation xml:lang="en">Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785-802. DOI: 10.1038/s41569-021-00559-8.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Баланова Ю.А., Имаева А.Э., Шальнова С.А. и др. Поведенческие факторы риска в российской популяции: фокус на потребление табака. Результаты исследования ЭССЕ-РФ3. Профилактическая медицина. 2024;27(10):36-44. DOI: 10.17116/profmed20242710136.</mixed-citation><mixed-citation xml:lang="en">Balanova YuA, Imaeva AE, Shalnova SA, et al. Behavioral risk factors in the Russian population: focus on tobacco consumption. The ESSE-RF3 study results. Russian Journal of Preventive Medicine. 2024;27(10):36-44. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Шальнова С.А., Метельская В.А., Куценко В.А. и др. Холестерин, не входящий в состав липопротеинов высокой плотности: современный ориентир оценки нарушений липидного обмена. Рациональная Фармакотерапия в Кардиологии. 2022;18(4):366-75. DOI: 10.20996/1819-6446-2022-07-01.</mixed-citation><mixed-citation xml:lang="en">Shalnova SA, Metelskaya VA, Kutsenko VA, et al. Non-High Density Lipoprotein Cholesterol: A Modern Benchmark for Assessing Lipid Metabolism Disorders. Rational Pharmacotherapy in Cardiology. 2022;18(4):366-75. 2022;18(4):366-75. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Svinin GE, Kutsenko VA, Shalnova SA, et al. Validation of SCORE2 on a sample from the Russian population and adaptation for the very high cardiovascular disease risk region. PLoS One. 2024;19(4):e0300974. DOI: 10.1371/journal.pone.0300974.</mixed-citation><mixed-citation xml:lang="en">Svinin GE, Kutsenko VA, Shalnova SA, et al. Validation of SCORE2 on a sample from the Russian population and adaptation for the very high cardiovascular disease risk region. PLoS One. 2024;19(4):e0300974. DOI: 10.1371/journal.pone.0300974.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ерина А.М., Усольцев Д.А., Бояринова М.А. и др. Потребность в назначении гиполипидемической терапии в российской популяции: сравнение шкал SCORE и SCORE2 (по данным исследования ЭССЕ-РФ). Российский кардиологический журнал. 2022;27(5):5006. DOI: 10.15829/1560-4071-2022-5006.</mixed-citation><mixed-citation xml:lang="en">Erina AM, Usoltsev DA, Boyarinova MA, et al. Appointment of lipid-lowering therapy in the Russian population: comparison of SCORE and SCORE2 (according to the ESSE-RF study). Russian Journal of Cardiology. 2022;27(5):7-13. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Научно-организационный комитет проекта ЭССЕ-РФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследования. Профилактическая медицина. 2013;16(6):25-34.</mixed-citation><mixed-citation xml:lang="en">Scientific Organizing Committee of the ESSE-RF. Epidemiology of cardiovascular diseases in different regions of Russia (ESSE-RF). The rationale for and design of the study. Profilakticheskaya Meditsina. 2013;16(6):25-34. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Шальнова С.А., Баланова Ю.А. и др. Российская прогностическая шкала «ФЕНИКС» — новый отечественный инструмент для оценки кардиоваскулярного риска. Кардиоваскулярная терапия и профилактика. 2025;24(9):4510. DOI: 10.15829/1728-8800-2025-4510.</mixed-citation><mixed-citation xml:lang="en">Drapkina O.M., Shalnova S.A., Balanova Yu.A., et al. The Russian prognostic scale “PHOENIX” — a novel domestic tool for cardiovascular risk assessment. Cardiovascular Therapy and Prevention. 2025;24(9):4510. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988;41(2):105-14. DOI: 10.1016/0895-4356(88)90084-4.</mixed-citation><mixed-citation xml:lang="en">The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988;41(2):105-14. DOI: 10.1016/0895-4356(88)90084-4.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Капустина А.В., Деев А.Д., Худяков М.Б., Шальнова С.А. Характеристика здоровья лиц в возрасте 55 лет и старше, отказавшихся от обследования. Опыт когортного эпидемиологического исследования. Профилактическая медицина. 2015;18(6):40-6. DOI: 10.17116/profmed201518640-46.</mixed-citation><mixed-citation xml:lang="en">Kapustina AV, Deev AD, Khudiakov MB, Shalnova SA. Characteristics of the healthy status of people aged 55 years and over who have refused to be examined. Experience of a cohort epidemiological survey. Russian Journal of Preventive Medicine. 2015;18(6):40-6. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Капустина А.В., Евстифеева С.Е., Муромцева Г.А. и др. Изучение витального статуса и нефатальных сердечно-сосудистых осложнений на проспективном этапе когортного исследования «Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в различных регионах Российской Федерации (ЭССЕ-РФ)». Профилактическая медицина. 2014;17(6):26-31.</mixed-citation><mixed-citation xml:lang="en">Kapustina AV, Evstifeeva SE, Muromtseva GA, et al. Investigation of the vital status and nonfatal cardiovascular events in the prospective cohort study of the epidemiology of cardiovascular diseases and their risk factors in different regions of the Russian Federation (ESSE-RF). Russian Journal of Preventive Medicine. 2014;17(6):26-31. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Шальнова С.А., Баланова Ю.А., Вилков В.Г. и др. Как понимать и использовать результаты эпидемиологических исследований в практике здравоохранения. Методическое пособие. Кардиоваскулярная терапия и профилактика. 2022;21(11):3475. DOI: 10.15829/1728-8800-2022-3475.</mixed-citation><mixed-citation xml:lang="en">Shalnova SA, Balanova YuA, Vilkov VG, et al. How to interpret and use the results of epidemiological studies in healthcare practice. Methodological Rationale. Cardiovascular Therapy and Prevention. 2022;21(11):3475. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jafari A, Rajabi A, Gholian-Aval M, et al. National, regional, and global prevalence of cigarette smoking among women/females in the general population: a systematic review and meta-analysis. Environ Health Prev Med. 2021;26(1):5. DOI: 10.1186/s12199-020-00924-y.</mixed-citation><mixed-citation xml:lang="en">Jafari A, Rajabi A, Gholian-Aval M, et al. National, regional, and global prevalence of cigarette smoking among women/females in the general population: a systematic review and meta-analysis. Environ Health Prev Med. 2021;26(1):5. DOI: 10.1186/s12199-020-00924-y.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Заирова А.Р., Рогоза А.Н., Ощепкова Е.В. и др. Стратификация сердечно-сосудистого риска с использованием шкалы SCORE2 в популяционной выборке взрослого городского населения и оценка ее эффективности по результатам 5-летнего наблюдения. Кардиоваскулярная терапия и профилактика. 2025;24(1):4184. DOI: 10.15829/1728-8800-2025-4184.</mixed-citation><mixed-citation xml:lang="en">Zairova AR, Rogoza AN, Oshchepkova EV, et al. SCORE2 cardiovascular risk stratification of an urban adult population sample and evaluation of its effectiveness based on 5-year follow-up. Cardiovascular Therapy and Prevention. 2025;24(1):4184. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">van Trier TJ, Snaterse M, Boekholdt SM, et al. Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort. Eur J Prev Cardiol. 2024;31(2):182-9. DOI: 10.1093/eurjpc/zwad318.</mixed-citation><mixed-citation xml:lang="en">van Trier TJ, Snaterse M, Boekholdt SM, et al. Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort. Eur J Prev Cardiol. 2024;31(2):182-9. DOI: 10.1093/eurjpc/zwad318.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Temtem M, Mendonça MI, Santos M, et al. Validation of the SCORE2 risk prediction algorithm in a Portuguese population: A new model to estimate 10-year cardiovascular disease incidence in Europe. Rev Port Cardiol. 2024;43(8):437-44. DOI: 10.1016/j.repc.2023.10.011.</mixed-citation><mixed-citation xml:lang="en">Temtem M, Mendonça MI, Santos M, et al. Validation of the SCORE2 risk prediction algorithm in a Portuguese population: A new model to estimate 10-year cardiovascular disease incidence in Europe. Rev Port Cardiol. 2024;43(8):437-44. DOI: 10.1016/j.repc.2023.10.011.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kist JM, Vos RC, Mairuhu ATA, et al. SCORE2 cardiovascular risk prediction models in an ethnic and socioeconomic diverse population in the Netherlands: an external validation study. EClinicalMedicine. 2023;57:101862. DOI: 10.1016/j.eclinm.2023.101862.</mixed-citation><mixed-citation xml:lang="en">Kist JM, Vos RC, Mairuhu ATA, et al. SCORE2 cardiovascular risk prediction models in an ethnic and socioeconomic diverse population in the Netherlands: an external validation study. EClinicalMedicine. 2023;57:101862. DOI: 10.1016/j.eclinm.2023.101862.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">van Apeldoorn JAN, Hageman SHJ, Harskamp RE, et al. Adding ethnicity to cardiovascular risk prediction: External validation and model updating of SCORE2 using data from the HELIUS population cohort. Int J Cardiol. 2024;417:132525. DOI: 10.1016/j.ijcard.2024.132525.</mixed-citation><mixed-citation xml:lang="en">van Apeldoorn JAN, Hageman SHJ, Harskamp RE, et al. Adding ethnicity to cardiovascular risk prediction: External validation and model updating of SCORE2 using data from the HELIUS population cohort. Int J Cardiol. 2024;417:132525. DOI: 10.1016/j.ijcard.2024.132525.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Sud M, Sivaswamy A, Austin PC, et al. Validation of the European SCORE2 models in a Canadian primary care cohort. Eur J Prev Cardiol. 2024;31(6). DOI: 10.1093/eurjpc/zwad352.</mixed-citation><mixed-citation xml:lang="en">Sud M, Sivaswamy A, Austin PC, et al. Validation of the European SCORE2 models in a Canadian primary care cohort. Eur J Prev Cardiol. 2024;31(6). DOI: 10.1093/eurjpc/zwad352.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Choi J, Sung S, Park SK, et al. SCORE and SCORE2 in East Asian Population: A Performance Comparison. JACC Asia. 2024;4(4):265-74. DOI: 10.1016/j.jacasi.2023.10.013.</mixed-citation><mixed-citation xml:lang="en">Choi J, Sung S, Park SK, et al. SCORE and SCORE2 in East Asian Population: A Performance Comparison. JACC Asia. 2024;4(4):265-74. DOI: 10.1016/j.jacasi.2023.10.013.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
